Amy L. Inselman
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
Also affiliated: National Institutes of Health (2004–2015); United States Food and Drug Administration (2013–2024); Southeast Missouri State University (1998–1999); National Institute of Environmental Health Sciences (2007–2015); The Nakamura Hajime Eastern Institute (2009); Food and Drug Administration (2015); Center for Systems Biology (2024); University of Tennessee at Knoxville (2002–2004)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Amy L. Inselman's research focuses on evaluating the reproductive and developmental toxicity potential of various substances, particularly botanicals, using animal models. She investigates screening strategies to identify these potentials, contributing to the regulation and understanding of drug safety. Her work has explored the incorporation of advanced techniques like MALDI mass spectrometry imaging to detect markers of toxicity, such as following in utero opioid exposures in mouse fetuses. Inselman has also examined the effects of coadministered substances on bone health in rat models and considered the broader implications of regulating drugs of abuse for research advancement and public health.
Her scholarship includes 50 publications and 1,004 citations, with an h-index of 14. She has collaborated with researchers at the National Center for Toxicological Research, including Richard D. Beger, E. Ellen Jones, Dustyn A. Barnette, and Sumit Sarkar, on multiple shared publications. Inselman's most recent publication dates to 2026, indicating recent activity in her research field.
Metrics
- h-index: 14
- Publications: 50
- Citations: 1,014
Selected Publications
-
Potential Effects of Prepubertal Exposure to Perfluorooctane Sulfonic Acid on the First Wave of Folliculogenesis in Young <scp>CD</scp> ‐1 Mice (2026)
-
A screening strategy for identifying the developmental and reproductive toxicity potential of botanicals (2026)
-
Regulating controlled substances to advance research and protect public health (2026)
-
The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses (2024)
-
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model (2024)
-
The benefits, limitations and opportunities of preclinical models for neonatal drug development (2022)
-
Potential mechanisms for phencyclidine/ketamine-induced brain structural alterations and behavioral consequences (2019)
-
Rebuttal to the comments by Dr. Yan Xu on the article “Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone” (2019)
-
Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone (2018)
-
Evaluation of Culture Time and Media in an <i>In Vitro</i> Testis Organ Culture System (2017)
-
Transcriptomics analysis of early embryonic stem cell differentiation under osteoblast culture conditions: Applications for detection of developmental toxicity (2017)
-
Effects of Culture Conditions on Maturation of Stem Cell‐Derived Cardiomyocytes (2016)
-
Effects of silver nanoparticles on human and rat embryonic neural stem cells (2015)
-
Developing osteoblasts as an endpoint for the mouse embryonic stem cell test (2015)
-
Effects of Maternal and Lactational Exposure to 2‐Hydroxy‐4‐Methoxybenzone on Development and Reproductive Organs in Male and Female Rat Offspring (2015)
Collaboration Network
Top Collaborators
- The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model
- The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
Similar Researchers
Based on overlapping research topics